PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells

The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metabolism. To determine whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression. PKM2 de...

Full description

Bibliographic Details
Main Authors: Li, Jie (Author), Sasaki, Mika (Author), Horner, James W (Author), Burga, Laura N (Author), Xie, Jianxin (Author), Jurczak, Michael J (Author), DePinho, Ronald A (Author), Clish, Clary B (Author), Kibbey, Richard G (Author), Wulf, Gerburg M (Author), Di Vizio, Dolores (Author), Mills, Gordon B (Author), Cantley, Lewis C (Author), Israelsen, William James (Contributor), Dayton, Talya L. (Contributor), Davidson, Shawn M. (Contributor), Fiske, Brian Prescott (Contributor), Hosios, Aaron Marc (Contributor), Bellinger, Gary (Contributor), Yu, Yimin (Contributor), Jacks, Tyler E. (Contributor), Vander Heiden, Matthew G. (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Elsevier, 2017-07-10T18:31:09Z.
Subjects:
Online Access:Get fulltext
LEADER 03870 am a22006973u 4500
001 110601
042 |a dc 
100 1 0 |a Li, Jie  |e author 
100 1 0 |a Massachusetts Institute of Technology. Department of Biology  |e contributor 
100 1 0 |a Koch Institute for Integrative Cancer Research at MIT  |e contributor 
100 1 0 |a Israelsen, William James  |e contributor 
100 1 0 |a Dayton, Talya L.  |e contributor 
100 1 0 |a Davidson, Shawn M.  |e contributor 
100 1 0 |a Fiske, Brian Prescott  |e contributor 
100 1 0 |a Hosios, Aaron Marc  |e contributor 
100 1 0 |a Bellinger, Gary  |e contributor 
100 1 0 |a Yu, Yimin  |e contributor 
100 1 0 |a Jacks, Tyler E.  |e contributor 
100 1 0 |a Vander Heiden, Matthew G.  |e contributor 
700 1 0 |a Sasaki, Mika  |e author 
700 1 0 |a Horner, James W.  |e author 
700 1 0 |a Burga, Laura N.  |e author 
700 1 0 |a Xie, Jianxin  |e author 
700 1 0 |a Jurczak, Michael J.  |e author 
700 1 0 |a DePinho, Ronald A.  |e author 
700 1 0 |a Clish, Clary B.  |e author 
700 1 0 |a Kibbey, Richard G.  |e author 
700 1 0 |a Wulf, Gerburg M.  |e author 
700 1 0 |a Di Vizio, Dolores  |e author 
700 1 0 |a Mills, Gordon B.  |e author 
700 1 0 |a Cantley, Lewis C.  |e author 
700 1 0 |a Israelsen, William James  |e author 
700 1 0 |a Dayton, Talya L.  |e author 
700 1 0 |a Davidson, Shawn M.  |e author 
700 1 0 |a Fiske, Brian Prescott  |e author 
700 1 0 |a Hosios, Aaron Marc  |e author 
700 1 0 |a Bellinger, Gary  |e author 
700 1 0 |a Yu, Yimin  |e author 
700 1 0 |a Jacks, Tyler E.  |e author 
700 1 0 |a Vander Heiden, Matthew G.  |e author 
245 0 0 |a PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells 
260 |b Elsevier,   |c 2017-07-10T18:31:09Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/110601 
520 |a The pyruvate kinase M2 isoform (PKM2) is expressed in cancer and plays a role in regulating anabolic metabolism. To determine whether PKM2 is required for tumor formation or growth, we generated mice with a conditional allele that abolishes PKM2 expression without disrupting PKM1 expression. PKM2 deletion accelerated mammary tumor formation in a Brca1-loss-driven model of breast cancer. PKM2 null tumors displayed heterogeneous PKM1 expression, with PKM1 found in nonproliferating tumor cells and no detectable pyruvate kinase expression in proliferating cells. This suggests that PKM2 is not necessary for tumor cell proliferation and implies that the inactive state of PKM2 is associated with the proliferating cell population within tumors, whereas nonproliferating tumor cells require active pyruvate kinase. Consistent with these findings, variable PKM2 expression and heterozygous PKM2 mutations are found in human tumors. These data suggest that regulation of PKM2 activity supports the different metabolic requirements of proliferating and nonproliferating tumor cells. 
520 |a National Institutes of Health (U.S.) (Grant R01CA168653) 
520 |a National Institutes of Health (U.S.) (Grant 5P01CA117969) 
520 |a National Institutes of Health (U.S.) (Grant P30CA147882) 
520 |a National Institutes of Health (U.S.) (Grant 5P30CA14051) 
520 |a National Institutes of Health (U.S.) (Grant 5K08CA136983) 
520 |a National Institutes of Health (U.S.) (Grant DK059635) 
520 |a National Institutes of Health (U.S.) (Grant R01DK092606) 
520 |a National Institutes of Health (U.S.) (Grant R00CA131472) 
520 |a National Institutes of Health (U.S.) (Grant R01GM056203) 
520 |a American Diabetes Association (Grant 7-12-BS-09) 
520 |a Smith Family Foundation 
520 |a Burroughs Wellcome Fund 
520 |a Damon Runyon Cancer Research Foundation 
520 |a Stern Family 
546 |a en_US 
655 7 |a Article 
773 |t Cell